However, adaptive resistance may not be the only factor in driving PD-L1 expression as it can be up-regulated in breast cancer by other mechanisms such as PTEN loss and ensuing activation of the PI3K pathway [37]. The gene discussed is PTEN; the disease is breast carcinoma.